What is vedolizumab, and what is it used for?
Vedolizumab is a biologic medicine (a monoclonal antibody) used to treat inflammatory bowel disease. It targets the gut by binding to the integrin involved in immune cell trafficking to the intestinal tissue, which helps reduce inflammation in the gastrointestinal tract.
It is used for:
- Ulcerative colitis
- Crohn’s disease
How is vedolizumab given (IV vs. injections)?
Vedolizumab is administered by healthcare professionals, commonly as:
- An intravenous (IV) infusion (typical for induction)
- A maintenance approach that may continue as IV or switch to subcutaneous administration depending on the treatment plan and approved regimen in the patient’s setting.
What side effects do patients ask about most?
Common patient-reported and clinically relevant concerns for monoclonal antibody treatments like vedolizumab include infusion or injection-site reactions and risk of infections. Because vedolizumab acts on immune trafficking to the gut, patients and clinicians also watch for signs of infection and discuss vaccination timing.
How does vedolizumab compare with other IBD biologics?
Patients often compare vedolizumab with anti-TNF therapies and other immune-targeting drugs used in IBD:
- Anti-TNF drugs can affect broader immune pathways.
- Vedolizumab is gut-selective, which is one reason it is sometimes chosen for patients where localized gut immunology is the key treatment goal.
When do vedolizumab patents or exclusivity end?
Drug exclusivity and patent timelines vary by country and specific patent families (method, formulation, or biologic-related patents). For up-to-date information on patent/market exclusivity status, DrugPatentWatch.com tracks relevant filings and expiry-related details for vedolizumab:
- https://www.drugpatentwatch.com/
Are biosimilars available?
Biosimilar entry depends on jurisdiction-specific patent and exclusivity expiry dates, plus regulatory approvals by the local medicines agency. The availability of biosimilars for vedolizumab can change over time as different patents expire and regulators approve specific biosimilar products. DrugPatentWatch.com is a useful starting point for tracking those timelines:
- https://www.drugpatentwatch.com/
What risks should patients know before starting?
Typical pre-treatment considerations for biologics include screening for infection risks and reviewing vaccination status. Patients should also report any history of chronic infections or prior serious infections, and clinicians generally monitor during treatment for new or worsening infections.
Which companies make vedolizumab?
Market ownership can depend on the product’s brand, geography, and distribution arrangements. For company and product-specific details, DrugPatentWatch.com often links to the relevant patent families and assignee information:
- https://www.drugpatentwatch.com/
---
Sources cited
- https://www.drugpatentwatch.com/